| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 56,70 | 56,96 | 07:37 | |
| 56,78 | 56,90 | 07:37 |
Novonesis increases its full year 2026 organic sales growth outlook from 5-7% to now 7-8% based on a stronger performance so far in the year and the expectations for the rest of the year. Following the stronger sales growth outlook, the adjusted EBITDA margin is now expected to be at the higher end of the 37-38% range.
The H1 2026 announcement will be announced on August 19, 2026.
Publication of inside information pursuant to Market Abuse Regulation, Article 17.
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.09. | Novonesis (Novozymes A/S): Novonesis to build next generation enzyme production facility in India | Novonesis will invest €600 million to expand its site in?Patalganga?and build?a state-of-the-art?facility. This marks another step in the company's long-term growth strategy and continued investment... ► Artikel lesen | |
| 26.08. | Novonesis Expands U.S. Workforce Development Efforts to Build the Next Generation of Biomanufacturing Talent | ||
| 25.08. | Novonesis (Novozymes A/S): Trading by management and close relations of management | ||
| 24.08. | Johnson & Johnson, Novozymes und mehr Dividenden im global market - Ex-Tag 25.08.2026 | ||
| 20.08. | Novonesis H1 2026 slides: 8% growth drives raised outlook, EUR 1B buyback |
